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Previous evidence has indicated that downregulated ADAM10 gives rise to epileptic 
seizures in Alzheimer’s disease, and this study investigated the association of ADAM10 
with temporal lobe epilepsy (TLE) from a genetic perspective. A total of 496 TLE patients 
and 528 healthy individuals were enrolled and genotyped for ADAM10 promoter variants 
(rs653765 G > A and rs514049 A > C). The alleles, genotypes, and haplotypes were then 
compared with clarify the association of these variants with TLE and their impacts upon 
age at onset, initial seizure types before treatments, and responses to drug treatments. 
In cohorts I, II, and I + II, the frequencies of the A allele and AA genotype at rs514049 
were consistently increased in the cases compared with the controls (p = 0.020 and 
p = 0.009; p = 0.008 and p = 0.009; p = 0.000 and p = 0.000; q = 0.003 and q = 0.002, 
respectively). In contrast, the frequency of the AC haplotype (rs653765–rs514049) 
decreased in cohorts I + II (p = 0.013). Further analyses of the TLE patients indicated 
that the AA genotype functioned as a predisposing factor to drug-resistant TLE and the 
AC haplotype as a protective factor against generalized tonic–clonic seizures (GTCS) and 
drug-resistant TLE. This study is the first to demonstrate an association of the ADAM10 
promoter variants with TLE. In particular, the AA genotype and AC haplotype showed 
their effects upon GTCS and drug-resistant TLE.
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inTrODUcTiOn
The past decades have witnessed great efforts to investigate temporal lobe epilepsy (TLE), but its 
pathogenesis remains unclear (1). Notably, some brain diseases are associated with increased risks of 
seizures, especially Alzheimer’s disease (AD), with a 6- to 10-fold risk of developing seizures (2–8). 
Interestingly, AD usually undergoes abnormal alterations in temporal lobes, whereas TLE experi-
ences a certain degree of cognitive dysfunction, suggesting that these two common diseases may 
share underlying mechanisms. Hence, further exploration of key modulators in AD may represent 
a novel way to understand TLE.
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Indeed, the deposition of amyloid β (Aβ), a pathological 
hallmark of AD, has been considered a probable link to epilep-
tic seizures by increased neuronal destruction in response to 
excitotoxicity (9, 10). ADAM10, a key α-secretase for amyloid 
precursor protein (APP), functions in the formation of soluble 
APP alpha (sAPPα), which is a competitive biological process 
that inhibits the cleavage of APP from the overproduction of 
neurotoxic Aβ (11). Strikingly, the levels of ADAM10 decrease in 
the pyramidal cell layers of the rat hippocampus after status epi-
lepticus (12) and in the brain tissues of AD patients (13). After the 
gene encoding ADAM10 was knocked out in mice, the expression 
level of ADAM10 was downregulated in the brain cortex; this 
was accompanied by repetitive seizures (14), which indicate that 
insufficient expression of ADAM10 could represent a potential 
etiology of epileptic seizures in AD patients. Further research 
using a transgenic mouse model of experimental kainate-induced 
seizures uncovered the detailed role of ADAM10, and mice with 
moderate overexpression of ADAM10 suffered from weaker 
seizures with a shorter recovery period in comparison to mice 
with low expression of ADAM10 (15). Hence, ADAM10 should 
play a protective role against epileptic activities.
In light of the single nucleotide polymorphism database 
(dbSNP), 6,771 polymorphic sites exist in the sequence of the 
ADAM10 gene. In theory, these SNPs might influence predisposi-
tion to related diseases by altering the expression of ADAM10 
or certain linkage correlations. Among these are rs653765 and 
rs514049, two variants of great concern, located in the promoter 
region and 5′ untranslated region (UTR) of the ADAM10 gene, 
respectively. Previous studies have documented their association 
with AD (16–19). In particular, Bekris and colleagues found that 
the AC haplotype (rs653765–rs514049) was associated with a 
lower level of ADAM10 protein in the postmortem hippocampus 
of AD patients (17). Moreover, these researchers further observed 
that sAPPα expression was lower in the cerebrospinal fluid of 
AD patients with the AC haplotype in comparison to controls 
with the same haplotype, which is consistent with the insufficient 
expression of ADAM10 in AD patients. More importantly, the 
AC haplotype was confirmed to reduce transcriptional activities 
of the ADAM10 promoter through a dual-luciferase reporter gene 
assay system (17). Nonetheless, the association of ADAM10 with 
TLE remains undetermined from the perspective of genetics.
To identify whether the promoter variants (rs653765 and 
rs514049) function in TLE, this study recruited two independ-
ent cohorts from the Han Chinese population, with the goal of 
clarifying the genetic implications of ADAM10 in the occurrence 
and development of TLE.
MaTerials anD MeThODs
ethical standards
This study was approved by the Ethics Committees of the Affiliated 
Hospital of Guangdong Medical University, the First Affiliated 
Hospital of Harbin Medical University, the Beijing Tongren 
Hospital, the Central People’s Hospital of Zhanjiang, and the First 
People’s Hospital of Pingdingshan and was performed according 
to the Declaration of Helsinki. Informed-consent documents 
were signed by all subjects before their enrollments.
subject enrollment
Initially, 335 TLE patients (male/female: 170/165; mean age: 
31 ± 15 years) and 325 healthy individuals (male/female: 185/140; 
mean age: 31 ± 10 years) were enrolled into cohort I. All of the 
subjects were recruited from three hospitals (the First Affiliated 
Hospital of Harbin Medical University, the Affiliated Hospital 
of Guangdong Medical University, and the Beijing Tongren 
Hospital). To validate the genotyping findings in cohort I, an 
additional group of 161 TLE patients (male/female: 79/82; mean 
age: 33 ±  15  years) and 203 healthy individuals (male/female: 
104/99; mean age: 33 ± 16 years) was recruited from the Central 
People’s Hospital of Zhanjiang and the First People’s Hospital of 
Pingdingshan as cohort II. All of the subjects in cohorts I +  II 
were Han Chinese and constituted a total of 496 TLE patients and 
528 healthy individuals.
The gender, age, age at onset, and initial seizure types [such 
as complex partial seizures (CPS) and generalized tonic–clonic 
seizures (GTCS)] before treatments were documented at the 
time of enrollment. Seizure frequencies were further recorded 
after their enrollments through field or telephone investigation. 
According to the definition of drug-resistant epilepsy (DRE) pro-
posed by the International League Against Epilepsy (ILAE) (20), 
the responses to drug treatments of the TLE patients were defined 
as follows: drug-resistant cases were determined in line with the 
absence of a change or a reduction (<60%) in seizure frequency 
after 1 year of treatment with a schedule of two or more tolerated 
and appropriately selected antiepileptic drugs; the remaining 
were considered as drug-sensitive cases. In addition, all subjects 
whose blood samples failed to be genotyped were excluded from 
the study.
Dna extraction and genotyping for 
the aDaM10 snPs
Peripheral blood samples were collected from each subject. 
DNA was then extracted using the Genomic DNA Extraction 
Kit (Tiangen Biotech, Beijing, China) and temporarily stored at 
−80°C prior to genotyping. The DNA samples were genotyped 
for the ADAM10 SNPs (rs514049 and rs653765) using the ABI 
PRISM SNaPshot method (Applied Biosystems, Carlsbad, CA, 
USA). The primers used in multiplex PCR for amplification of two 
target fragments (121 and 155 bp, respectively) were as follows: 
rs514049, 5′-TGAGGACCTTCCCTTGGGCTAA-3′ (forward 
primer) and 5′-GGTGCACCAAGAGAGGCAGAAA-3′ (reverse 
primer); rs653765, 5′-CGGCAACGCTCCTAGCTCCT-3′ 
(forward primer) and 5′-CGCGTCACGTGGTGAGGA-AG-3′ 
(reverse primer). The primers used in SNaPshot PCR for primer 
extension were 5′-TTTTTTTTTTTTTTTTTTTTTTTTT AAG 
CAGGGCTGCTTTCGACTTCTT-AA-3′ (rs514049) and 
5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTT 
TT-GAGGCGGAGGTCTGAGTTTCGA-3′ (rs653765).
The multiplex PCR reaction mix was composed of 1× 
HotStarTaq buffer, 3.0 mM Mg2+, 0.3 mM dNTP, 1 U HotStarTaq 
polymerase, 1 μl DNA template, and 1 μl primer mix. The PCR 
program was as follows: an initial cycle at 95°C/2 min; 11 cycles 
of 94°C/20 s, 65°C/40 s, and 72°C/90 s; 24 cycles of 94°C/20 s, 
59°C/30  s, and 72°C/90  s; and a final cycle at 72°C/2  min. 
TaBle 1 | subject characteristics.
cases controls p Values
gender (male/female, n)
Cohort I 170/165 185/140 0.112
Cohort II 79/82 104/99 0.682
Cohorts I + II 249/247 289/239 0.147
age (mean ± sD, years)
Cohort I 31 ± 15 31 ± 10 0.862
Cohort II 33 ± 15 33 ± 16 0.617
Cohorts I + II 32 ± 15 32 ± 13 0.743
Other characteristics in cohorts i + ii
Age at onset (mean ± SD, years) 21 ± 14 – –
initial seizure types before treatment (n)
CPS/non-CPS cases 332/164 – –
GTCS/non-GTCS cases 184/312 – –
responses to drug treatment
Seizure frequency (mean ± SD, times/month) 7 ± 3 – –
Drug-resistant/sensitive cases (n) 246/250 – –
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The products were then purified with the assistance of Shrimp 
alkaline phosphatase (SAP) and exonuclease I. The SNaPshot 
PCR reaction mix contained 5 μl SNaPshot Multiplex Kit, 2 μl 
purified PCR products, 1 μl primer mix, and 2 μl ultrapure H2O. 
The PCR program was as follows: an initial cycle at 96°C/1 min; 
28 cycles of 96°C/10 s, 55°C/5 s, and 60°C/30 s; and a final cycle 
at 4°C/2  min. After further purification by SAP, the extension 
products were analyzed using the ABI 3730xl DNA Analyzer 
and GeneMapper 4.1 (Applied Biosystems, Carlsbad, CA, USA). 
Finally, 5% of samples were randomly selected for genotyping for 
quality control in an independent trial. The genotyping results 
had to be entirely consistent with the primary results, otherwise 
the remaining (95% of samples) would be genotyped again to 
find the discordant samples, which would then be excluded from 
the study.
statistical analyses
The measurement data are shown as the means  ±  SD and 
compared using Student’s t-test. The enumeration data were 
compared using Chi-squared test or Fisher’s exact test. Logistic 
regression was used to correct bias of confounding factors, 
such as age and gender, and q values were calculated using 
Bonferroni correction for adjusting false positive results in 
multiple-time statistics. Most statistical analyses were carried 
out by SPSS 19.0 (IBM, NY, USA), and a two-tailed p ≤ 0.05 
was considered significant. In addition, power analyses were 
performed by Quanto 1.2 (University of Southern California, 
LA, USA) and haplotype analyses by Haploview 4.2 (Daly Lab, 
Cambridge, MA, USA).
resUlTs
subject characteristics
In total, this study enrolled 496 TLE patients and 528 healthy 
individuals. No significant differences in gender or age were 
observed between the cases and the controls in cohorts I, II, and 
I + II (all p values >0.05). In addition to gender and age, other 
characteristics of the TLE patients in cohorts I + II, including age 
at onset, initial seizure types before treatments, and responses to 
drug treatments, are shown in Table 1.
Data evaluations
All samples were successfully genotyped in this study. The 
frequency distributions of the ADAM10 SNPs (rs653765 and 
rs514049) in the case and control groups complied with Hardy–
Weinberg equilibrium. Power analyses using a log-additive mode 
showed that this study would have 99.8% power for rs653765 and 
90.7% power for rs514049 to detect a genotype with an odds ratio 
of 1.7 at a significance level of 0.05.
Frequency Distributions of the 
aDaM10 snPs
In cohort I, the frequencies of the A allele and AA genotype at 
rs514049 A >  C significantly increased in the cases compared 
with the controls (Table 2, p = 0.020 and p = 0.009, respectively). 
Moreover, their frequencies simultaneously increased in the cases 
compared with the controls in cohorts II (Table  2, p =  0.008 
and p = 0.009, respectively) and I + II (Table 3, p = 0.003 and 
p = 0.002, respectively), which confirmed the findings in cohort 
I. These results indicate that the A allele and AA genotype could 
be associated with predisposition to TLE. However, no significant 
differences were observed in the ADAM10 SNPs at rs653765 
G > A in the study.
As shown in Figure 1, a haplotype block (rs653765–rs514049, 
D′ value = 0.84) was successfully constructed in this study, which 
might influence promoter activities of the ADAM10 gene due to 
its particular locus. The frequencies of the ADAM10 haplotypes 
were then compared between the cases and controls in cohorts 
I + II. As a result, the case ratio of the AC haplotype was dem-
onstrated to be lower than the control ratio (Table  4, 4.3 vs. 
6.8%, p = 0.013), indicating that the AC haplotype likely exerts 
protective effects against TLE by weakening the transcriptional 
activities of the ADAM10 gene.
impacts of the aDaM10 snPs on age at 
Onset of Tle
Based on the positive findings above, this study further evaluated 
the impacts of the AA genotype and AC haplotype on the age 
at onset of TLE patients in cohorts I + II. However, as shown 
in Figure  2, no significant differences in age at onset were 
observed between the AA genotype (n = 459, 21 ± 14 years) 
and the AC + CC genotypes (n = 37, 19 ± 16 years) or between 
the AC haplotype (n =  6, 30 ±  3  years) and the GA +  AA 
haplotypes (n  =  354, 22  ±  14  years) after adjustments for 
gender and age (p = 0.454 and p = 0.392, respectively). These 
findings indicated no association of the ADAM10 SNPs with 
age at onset of TLE.
impacts of the aDaM10 snPs on initial 
seizure Types of Tle
Similar to age at onset, this study also explored the impacts of 
the AA genotype and AC haplotype on the initial seizure types 
of the TLE patients before treatment in cohorts I + II. As shown 
FigUre 1 | haplotype block (rs653765–rs514049) and its functional implications. According to the GRCh38.p2 primary assembly, ADAM10 is encoded in 
Homo sapiens chromosome 15 (58,595,204–58,749,978). Its first exon and an upstream part of the first intron are individually shown as a light/dark green bar and a 
blue line, respectively. The light part of the green bar represents the 5′UTR of the ADAM10 gene. In the visual, rs653765 and rs514049 are located upstream of the 
transcription start site (−186 bp) and the 5′UTR of the ADAM10 gene, respectively. Using Haploview 4.2, a haplotype block (rs653765–rs514049, D′ value = 0.84) 
was further constructed in this study, implying its functional implications with TLE through influencing promoter activities of the ADAM10 gene.
TaBle 3 | alleles and genotypes of the aDaM10 snPs in the cases and controls of cohorts i + ii.
cases n (%) controls n (%) Ors (95% ci) p Values q Values
rs653765 g > a
G/A 832 (83.8)/160 (16.4) 874 (82.8)/182 (17.2) 1.07 (0.85–1.35) 0.582 4.656
GG/GA/AA 348 (70.2)/136 (27.4)/12 (2.4) 363 (68.7)/148 (28.0)/17 (3.2) 1.07 (0.85–1.35) 0.581 4.647
GG/GA + AA 348 (70.2)/148 (29.8) 363 (68.7)/165 (31.3) 1.05 (0.80–1.38) 0.716 5.725
GG + GA/AA 484 (97.6)/12 (2.4) 511 (96.8)/17 (3.2) 1.33 (0.63–2.81) 0.459 3.673
rs514049 a > c
A/C 949 (95.7)/43 (4.3) 968 (91.7)/88 (8.3) 1.97 (1.35–2.87) 0.000 0.003
AA/AC/CC 459 (92.5)/31 (6.3)/6 (1.2) 448 (84.9)/72 (13.6)/8 (1.5) 2.01 (1.29–3.11) 0.002 0.016
AA/AC + CC 459 (92.5)/37 (7.5) 448 (84.8)/80 (15.2) 2.18 (1.44–3.29) 0.000 0.002
AA + AC/CC 490 (98.8)/6 (1.2) 520 (98.5)/8 (1.5) 1.24 (0.43–3.59) 0.697 5.576
ORs and p values have been adjusted for gender and age; q values were obtained using Bonferroni correction.
TaBle 2 | alleles and genotypes of the aDaM10 snPs in the cases and controls of cohorts i and ii.
cohort i cohort ii
cases n (%) controls n (%) p Values cases n (%) controls n (%) p Values
rs653765 g > a
G/A 560 (83.6)/110 (16.4) 538 (82.8)/112 (17.2) 0.816 272 (84.5)/50 (15.5) 336 (82.8)/70 (17.2) 0.582
GG/GA/AA 233 (69.6)/94 (28.1)/8 (2.4) 223 (68.6)/92 (28.3)/10 (3.1) 0.922 115 (71.4)/42 (26.1)/4 (2.5) 140 (69.0)/56 (27.6)/7 (3.4) 0.584
GG/GA + AA 233 (69.6)/102 (30.5) 229 (68.6)/102 (31.4) 0.815 115 (71.4)/46 (28.6) 140 (69.0)/63 (31.0) 0.666
GG + GA/AA 327 (97.6)/8 (2.4) 315 (96.9)/10 (3.1) 0.635 157 (97.5)/4 (2.5) 196 (96.6)/7 (3.4) 0.592
rs514049 a > c
A/C 640 (95.5)/30 (4.5) 600 (92.3)/50 (7.7) 0.020 309 (96.0)/13 (4.0) 368 (90.6)/38 (9.4) 0.008
AA/AC/CC 309 (92.2)/22 (6.6)/4 (1.2) 278 (85.5)/44 (13.5)/3 (0.9) 0.100 150 (93.2)/9 (5.6)/2 (1.2) 170 (83.7)/28 (13.9)/5 (2.5) 0.017
AA/AC + CC 309 (92.2)/26 (7.8) 278 (85.5)/47 (14.56) 0.009 150 (93.2)/11 (6.8) 170 (83.7)/33 (16.3) 0.009
AA + AC/CC 331 (98.8)/4 (1.2) 322 (99.1)/3 (0.9) 0.691 159 (98.8)/2 (1.2) 198 (97.5)/5 (2.5) 0.398
p Values have been adjusted for gender and age.
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in Figure  3, the incidence of GTCS was significantly lower in 
carriers of the AC haplotype than the GA + AA haplotypes after 
adjusting for gender and age (p = 0.019), indicating the potential 
effects of the AC haplotype against GTCS. However, no significant 
differences in CPS were seen between the AC haplotype and the 
GA + AA haplotypes (p = 0.997) or in initial seizure types (CPS 
and GTCS) between the AA and AC + CC genotypes (p = 0.301 
and p = 0.897, respectively).
FigUre 2 | impacts of the aa genotype (a) and ac haplotype (B) on the age at onset of Tle cases in cohorts i + ii.
TaBle 4 | The aDaM10 haplotypes in the cases and controls of cohorts i + ii.
haplotypes Frequency ratios (%) case ratios (%) control ratios (%) p Values
rs653765–rs514049 GA 82.5 83.8 81.2 0.124
AA 11.1 11.9 10.4 0.311
AC 5.6 4.3 6.8 0.013
FigUre 3 | impacts of the aa genotype (a,B) and ac haplotype (c,D) on initial seizure types of the Tle cases before treatment in cohorts i + ii. 
* represents adjusted p < 0.05.
5
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FigUre 4 | impacts of the aa genotype (a,B) and ac haplotype (c,D) on response to drug treatment of Tle cases in cohorts i + ii. * and *** represent 
adjusted p < 0.05 and p < 0.001, respectively.
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impacts of the aDaM10 snPs on 
response to Drug Treatment of Tle
Finally, this study investigated the impacts of the AA genotype 
and AC haplotype on responses to drug treatment of TLE patients 
in cohorts I + II. As shown in Figure 4, the incidences of drug-
resistant cases and seizure frequencies were significantly higher 
in carriers of the AA genotype than the CC +  AC genotypes 
(p =  0.017 and p =  0.000, respectively) but were decreased in 
carriers of the AC haplotype compared with the GA  +  AA 
haplotypes (p = 0.038 and 0.015, respectively) after adjusting for 
gender, age, and age at onset. These findings strongly imply that 
the AA genotype and AC haplotype function in response to TLE 
drug treatments.
DiscUssiOn
Based on the protective effects of ADAM10 against epileptic 
seizures, this study was designed to investigate the association 
between ADAM10 and TLE from a genetic perspective. As 
expected, we first observed the roles of the promoter variants in 
TLE: the A allele and the AA genotype at rs514049 were associ-
ated with predisposition to TLE, whereas the AC haplotype 
(rs653765–rs514049) exerted protective effects against TLE. 
Further analyses of the TLE patients indicated that the AA 
genotype functioned as a predisposing factor to drug-resistant 
TLE and the AC haplotype as a protective factor against GTCS 
and drug-resistant TLE.
Temporal lobe epilepsy is the most common form of partial 
epilepsy in adolescents and adults. It is estimated that TLE 
represents almost half of all epileptic seizures in adults (21). 
Similarly, the age at onset fluctuated by a wide margin in this 
study, possibly because TLE is a disease with different genetic 
and environmental factors. To some extent, early-onset TLE in 
adolescents usually originates from autosomal dominant inher-
itance and inborn errors, such as familial mesial TLE, familial 
lateral TLE, malformation of cortical development, and neonatal 
hypoxic ischemic encephalopathy (22, 23). However, the etiolo-
gies of late-onset TLE in adults are relatively complex and remain 
elusive. In recent years, the coexistence of AD and epileptic sei-
zures has raised a great deal of concern (3–8). AD, a typical aging 
disease, shows a higher prevalence of epileptic seizures than the 
general population. In particular, as a key modulator against the 
deposition of Aβ in AD, ADAM10 protein plays a protective 
role against epileptic activities (11–14). Thus, we hypothesized 
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an association between the ADAM10 SNPs and age at onset of 
TLE. In this study, no association was observed between the 
ADAM10 promoter variants and age at onset of TLE. However, 
a genetic observation is not sufficient to deny the potential role 
of ADAM10 protein in late-onset TLE, which still deserves to be 
evaluated in future research.
The symptoms of TLE are highly complex, including, but not 
limited to, indescribable auras, automatisms, and autonomic 
phenomena (24). In clinical practice, they are often simplified as 
three seizure types: simple partial seizures (SPS), CPS, and GTCS. 
In comparison with localized SPS within temporal lobes, CPS and 
GTCS are more serious due to their additional involvements in 
disturbance of consciousness and secondary generation, respec-
tively. In light of anatomical location, CPS partly results from 
transient interception of the bilateral ascending reticular activat-
ing system (ARAS). GTCS is implicated in aberrant discharges of 
motor function areas in frontal lobes. CPS and GTCS do not rep-
resent the same activated networks; therefore, recognizing seizure 
types is necessary to locate seizures and unveil their pathogenic 
networks. Notably, the deposition of neurotoxic Aβ was found 
in frontal lobes (25–27) as well as temporal lobes, which implies 
that ADAM10 might also function in frontal lobes due to its nega-
tive regulation on Aβ. In this study, the incidence of GTCS was 
observed to be significantly lower in carriers of the AC haplotype, 
which further supports the involvement of ADAM10 in frontal 
lobes. In addition, considering the role of the AC haplotype in 
decreasing transcriptional activities of the ADAM10 gene (17), it 
should be a functional variant for protection against GTCS.
Despite the development of a large number of new-generation 
antiepileptic drugs in recent decades, DRE still accounts for 
approximately one-third of epileptic cases (28). Notably, DRE 
is merely a clinical syndrome in light of the definition proposed 
by the ILAE (20), and its main source is TLE. Currently, several 
hypotheses are thought to explain drug-resistant TLE, includ-
ing transporter abnormalities (involved in overexpression of 
P-glycoprotein, multiple drug resistance 1, and multidrug resist-
ance protein), loss of drug sensitivity, and seizures beget seizures 
by a cascade of events, such as neuronal damage, sprouting of neu-
ronal axons, and new synapse formation (29–34). Interestingly, 
the levels of Aβ were recently observed to increase in the temporal 
cortex and hippocampus of drug-resistant patients, but no extra-
cellular amyloid plaques were identified. This finding suggested 
that abnormal Aβ may function in the pathogenesis of drug-
resistant TLE, but not in the same manner as AD (35). Based on 
these findings, we speculate that downregulated ADAM10 might 
play a pathological role in drug-resistant TLE through enhancing 
expression of Aβ. In the case–control study, we first demonstrated 
the association of ADAM10 with drug-resistant TLE from the 
genetic perspective. Considering that the AC haplotype reduced 
transcriptional activities of the ADAM10 promoter (17), these 
findings strongly support the notion that the AA genotype and 
AC haplotype function as factors of predisposition to/protection 
against drug-resistant TLE, respectively.
Several limitations should be acknowledged in the study. First, 
the relationship between the expression of ADAM10 in epilep-
togenic foci and its promoter variants remains undetermined 
because almost all enrolled cases accepted drug treatments; 
thus, it is difficult to obtain surgical brain samples for further 
experiments. Second, a short evaluation time (1 year) was used 
to identify patients with drug-resistant TLE; however, we agree 
with Schiller and Najjar that drug resistance is a graded process 
(36). Longer evaluation cycles (≥2 years) would likely bring about 
different cohorts than the drug-resistant TLE cohort used in this 
study; thus, the susceptibility to/protection against drug-resistant 
TLE in this study needs to be extended with caution under the 
condition of other evaluation times. Third, all enrolled subjects 
were of Han Chinese descent, and the minor allele frequencies at 
rs653765/rs514049 (0.17/0.07) are different from those in other 
populations, according to the international HapMap project, such 
as Utah residents of Northern and Western European ancestry 
(0.30/0.36) and African ancestry in the Southwestern United 
States (0.26/0.17). Thus, caution should be exercised before 
generalizing these findings to other ethnic populations.
In summary, this study is the first to demonstrate the associa-
tion of the ADAM10 promoter variants (the A allele and AA 
genotype/the AC haplotype) with predisposition to/protection 
against TLE, respectively. In particular, the AA genotype and 
the AC haplotype show their effects upon GTCS and drug-
resistant TLE.
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